Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAIRA PASCHOIN DE OLIVEIRA CAMPOS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1497020861
CMS profile
4535410
Location
SANTA BARBARA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$158.80

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $158.80 6

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $121.18 4
ABBVIE INC. $37.62 2

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAIRA PASCHOIN DE OLIVEIRA CAMPOS

NPI 1497020861 · CMS profile ID 4535410

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SANTA BARBARA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497020861?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAIRA PASCHOIN DE OLIVEIRA CAMPOS, NPI 1497020861, CMS profile ID 4535410. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497020861?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MAIRA PASCHOIN DE OLIVEIRA CAMPOS, NPI 1497020861, CMS profile ID 4535410. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497020861?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MAIRA PASCHOIN DE OLIVEIRA CAMPOS, NPI 1497020861, CMS profile ID 4535410, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1497020861?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $158.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $28.1411/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135144695 CMS
Lilly USA, LLC $33.0910/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135153182 CMS
Lilly USA, LLC $30.0209/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135101745 CMS
Lilly USA, LLC $29.9305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135153180 CMS
ABBVIE INC. $19.0302/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103410805 CMS
ABBVIE INC. $18.5901/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103410803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16.13 1
PY2021 $54.86 3
PY2022 $12.65 1
PY2023 $117.20 5
PY2024 $158.80 6
PY2025 $126.46 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $74,102.09 54
PY2024 Principal investigator $38,521.67 55
PY2023 Principal investigator $42,367.44 17
PY2022 Principal investigator $48,467.61 12
PY2021 Principal investigator $2,779.87 1
PY2020 Principal investigator $96.30 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742167
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742165
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742978
Principal investigator 1 Genentech, Inc. $173.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681024
Principal investigator 1 Genentech, Inc. $114.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681080
Principal investigator 1 Genentech, Inc. $173.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681082
Principal investigator 1 Genentech, Inc. $114.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681096
Principal investigator 1 Genentech, Inc. $173.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681098
Principal investigator 1 Genentech, Inc. $114.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681100
Principal investigator 1 Genentech, Inc. $114.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681104
Principal investigator 1 Genentech, Inc. $173.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681114
Principal investigator 1 Genentech, Inc. $173.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681130
Principal investigator 1 Genentech, Inc. $114.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681142
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742163
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742970
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742972
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742976
Principal investigator 1 Genentech, Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680895
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742974
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742145
Principal investigator 1 Genentech, Inc. $53.00 09/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680455
Principal investigator 1 Genentech, Inc. $173.00 09/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680851
Principal investigator 1 Genentech, Inc. $53.00 09/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680589
Principal investigator 1 Genentech, Inc. $114.00 09/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680717
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742147
Principal investigator 1 Stemline Therapeutics Inc. $2,843.00 08/28/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1244136266
Principal investigator 1 Genentech, Inc. $1,500.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680573
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742149
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742151
Principal investigator 1 Genentech, Inc. $1,777.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680293
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742153
Principal investigator 1 Genentech, Inc. $53.00 06/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680137
Principal investigator 1 Genentech, Inc. $114.00 06/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680193
Principal investigator 1 Genentech, Inc. $173.00 06/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680253
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 06/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742566
Principal investigator 1 Genentech, Inc. $28.00 06/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680063
Principal investigator 1 Genentech, Inc. $227.00 06/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680103
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742155
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742564
Principal investigator 1 Genentech, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680085
Principal investigator 1 Genentech, Inc. $2,584.00 05/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680127
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 04/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742554
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742556
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742157
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742159
Principal investigator 1 Genentech, Inc. $28.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679883
Principal investigator 1 Genentech, Inc. $1,500.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679935
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742558
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742560
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742562
Principal investigator 1 Stemline Therapeutics Inc. $800.00 02/05/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1244136255
Principal investigator 1 Stemline Therapeutics Inc. $1,326.09 02/05/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) No dispute reported 06/30/2026 1244136262
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/31/2025 Non-covered Recipient Entity
Sansum Clinic - Santa Barbara Hematology Oncology Medical Group
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742161
Principal investigator 1 Genentech, Inc. $3,221.00 01/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679941